Painful Urination: Drugs That Cause It and Medications That Treat It

What Painful Urination Actually Means

Dysuria is the medical term for pain, burning, or discomfort during urination. It can originate anywhere along the lower urinary tract, from the bladder to the urethra, and occasionally signals problems in adjacent structures like the prostate or vaginal tissue. The sensation ranges from a mild sting to severe, sharp pain that discourages patients from voiding altogether.

How Common Is Dysuria?

Population-level data from the National Ambulatory Medical Care Survey show that dysuria accounts for approximately 5 to 15% of outpatient visits to primary care providers in the United States [1]. Women are disproportionately affected. A prospective cohort study published in the Archives of Internal Medicine found that about 12% of women report at least one episode of dysuria consistent with UTI annually [2]. Men experience dysuria less frequently, but when they do, it more often signals a complicated etiology requiring broader workup.

Infectious vs. Non-Infectious Causes

The differential diagnosis for dysuria splits into two broad categories. Infectious causes include bacterial cystitis, urethritis from Chlamydia trachomatis or Neisseria gonorrhoeae, and vulvovaginal candidiasis. Non-infectious causes include chemical irritation from hygiene products, atrophic vaginitis in postmenopausal women, interstitial cystitis, and drug-induced bladder toxicity [3]. Distinguishing between these categories determines whether antibiotics, hormonal therapy, or drug discontinuation is the correct response.

Drugs That Can Cause Painful Urination

Several prescription and over-the-counter medications are known to provoke dysuria as a side effect. Recognizing drug-induced dysuria is important because the treatment is often drug modification or cessation rather than adding another medication.

Cyclophosphamide and Hemorrhagic Cystitis

Cyclophosphamide, an alkylating agent used in cancer treatment and severe autoimmune disease, is the most well-documented cause of drug-induced bladder injury. Its hepatic metabolite acrolein concentrates in urine and directly damages the urothelium. Without prophylaxis, hemorrhagic cystitis occurs in 10 to 40% of patients receiving high-dose cyclophosphamide [4]. The AUA recommends concurrent mesna (2-mercaptoethane sulfonate sodium) and aggressive hydration to neutralize acrolein and reduce bladder toxicity [5].

SGLT2 Inhibitors

Canagliflozin, dapagliflozin, and empagliflozin work by promoting glucosuria, which creates a glucose-rich urinary environment favorable to bacterial and fungal growth. In the CANVAS trial (N=10,142), genital mycotic infections occurred in 26% of women and 7% of men on canagliflozin versus 3% and <1% on placebo [6]. These infections frequently present with dysuria as the chief complaint. The 2022 ADA Standards of Care advise monitoring for genitourinary symptoms in all patients started on SGLT2 inhibitors [7].

Other Medications Linked to Dysuria

Doxycycline and other tetracyclines can cause esophageal and urethral irritation, particularly when taken without adequate water. Ketamine, increasingly recognized in both recreational use and off-label depression treatment, causes a well-characterized cystitis syndrome with severe dysuria, frequency, and reduced bladder capacity in 20 to 30% of regular users [8]. Certain nonsteroidal anti-inflammatory drugs (NSAIDs), particularly tiaprofenic acid (withdrawn in several countries for this reason), have been associated with chemical cystitis presenting as dysuria and hematuria [9]. Bacillus Calmette-Guérin (BCG) intravesical therapy for bladder cancer causes irritative voiding symptoms including dysuria in up to 90% of patients, typically resolving within 48 hours of instillation [10].

First-Line Medications for Treating Dysuria From UTIs

Uncomplicated UTI is the most common treatable cause of dysuria. Antibiotic selection follows national and international guidelines that weigh efficacy against resistance patterns.

Nitrofurantoin

The 2019 AUA/CUA/SUFU guideline on recurrent uncomplicated UTI and the 2010 IDSA guideline both recommend nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days as a first-line option for uncomplicated cystitis [11]. A Cochrane review of 27 trials (N=8,837) confirmed that nitrofurantoin achieves clinical cure rates of 88 to 93% with minimal impact on gut flora and low resistance induction compared to fluoroquinolones [12]. Nitrofurantoin is contraindicated when creatinine clearance falls below 30 mL/min because inadequate drug concentration reaches the urine.

Trimethoprim-Sulfamethoxazole (TMP-SMX)

TMP-SMX 160/800 mg twice daily for 3 days remains a first-line agent where local E. Coli resistance rates stay below 20% [11]. The IDSA guideline states: "TMP-SMX should be avoided as empiric therapy when the prevalence of resistance among uropathogens exceeds 20% or when it has been used for a UTI in the preceding 3 months" [11]. In communities meeting the resistance threshold, susceptibility testing should guide its use.

Fosfomycin

A single 3 g oral dose of fosfomycin trometamol offers a convenient alternative, particularly for patients with documented multidrug-resistant organisms. A randomized noninferiority trial published in JAMA (N=513) comparing single-dose fosfomycin to 5-day nitrofurantoin found nitrofurantoin achieved clinical resolution in 70% vs. 58% for fosfomycin at 28 days, meaning fosfomycin did not meet the noninferiority margin [13]. It remains an option when first-line agents are not tolerated or when resistance profiles favor it.

Symptomatic Relief: Phenazopyridine and Beyond

While antibiotics address the infection, patients often want immediate pain relief. Several agents target the symptom of dysuria directly.

Phenazopyridine

Phenazopyridine hydrochloride is an azo dye that exerts a local analgesic effect on the urinary tract mucosa. The FDA-approved dosing is 200 mg three times daily for no more than 2 days when used alongside an antibiotic [14]. Extended use risks methemoglobinemia, hemolytic anemia (especially in G6PD-deficient patients), and hepatotoxicity. The drug turns urine bright orange, which is harmless but should be communicated to patients to prevent alarm and staining of contact lenses.

Urinary Analgesics and Antispasmodics

For dysuria associated with bladder spasm rather than infection, anticholinergic agents like oxybutynin (5 mg two to three times daily) or the beta-3 agonist mirabegron (25 to 50 mg daily) can reduce detrusor overactivity and associated discomfort [15]. These are not first-line for infectious dysuria but play a role in interstitial cystitis/bladder pain syndrome (IC/BPS) and post-procedural irritation. The AUA IC/BPS guideline (2022 amendment) recommends a stepwise approach beginning with patient education and behavioral modifications before progressing to oral medications [16].

Treating Dysuria From Non-Infectious Causes

Not all dysuria responds to antibiotics. Identifying the non-infectious etiology is essential to avoid unnecessary antimicrobial exposure.

Atrophic Vaginitis and Genitourinary Syndrome of Menopause

Estrogen deficiency thins the vaginal and urethral epithelium, raising local pH and reducing lactobacilli. This shift predisposes postmenopausal women to both dysuria and recurrent UTI. The 2022 North American Menopause Society (NAMS) position statement recommends low-dose vaginal estrogen as first-line therapy for genitourinary syndrome of menopause (GSM) [17]. A meta-analysis of 14 RCTs (N=2,682) found that vaginal estrogen cream or tablets reduced recurrent UTI episodes by 36 to 75% compared with placebo [18]. Vaginal estradiol 10 mcg inserts used twice weekly are the most commonly prescribed formulation.

Interstitial Cystitis/Bladder Pain Syndrome

IC/BPS causes chronic dysuria, pelvic pain, and urinary frequency without identifiable infection. The only FDA-approved oral medication for IC/BPS is pentosan polysulfate sodium (Elmiron) at 100 mg three times daily, though its use has been tempered by reports of pigmentary maculopathy with long-term exposure. A 2018 study published in Ophthalmology identified retinal toxicity in 6 of 91 patients (6.6%) exposed to pentosan polysulfate for a mean of 186 months [19]. Current AUA guidelines recommend discussing this risk and performing baseline ophthalmologic examination before initiation [16].

Drug-Induced Cystitis Management

When a medication is identified as the cause of dysuria, discontinuation or substitution is the primary intervention. For cyclophosphamide-related cystitis, the switch to ifosfamide with mesna or to a non-alkylating regimen may be appropriate depending on the oncologic context. For ketamine-associated cystitis, cessation of ketamine is the only intervention with consistent evidence of symptom reversal, though recovery can take months depending on the duration and dose of prior use [8].

Diagnostic Workup for Persistent Dysuria

A systematic diagnostic approach prevents both undertreatment and antibiotic overuse.

Initial Assessment

The 2019 European Association of Urology (EAU) guideline on urological infections recommends urinalysis and urine culture as the standard initial evaluation for dysuria [20]. Dipstick testing for leukocyte esterase and nitrites has a sensitivity of approximately 75% and specificity of 82% for UTI, meaning a negative dipstick does not reliably exclude infection in symptomatic patients [21]. Clean-catch midstream urine culture with colony counts of 10³ CFU/mL or higher in symptomatic women is now accepted as diagnostically significant, a threshold lower than the traditional 10⁵ CFU/mL cutoff that the IDSA revised in 2010 [11].

When to Pursue Advanced Testing

Cystoscopy, pelvic imaging, or urodynamic studies become relevant when dysuria persists beyond 4 to 6 weeks despite appropriate empiric therapy, when hematuria accompanies the pain, or when anatomic abnormality is suspected. The American College of Obstetricians and Gynecologists (ACOG) recommends referral to urology or urogynecology for women with recurrent or refractory dysuria that does not respond to standard UTI treatment [22].

Special Populations: Pregnancy, Older Adults, and Men

Dysuria management shifts based on patient demographics and comorbidities.

Dysuria in Pregnancy

Asymptomatic bacteriuria (ASB) occurs in 2 to 10% of pregnancies and, left untreated, progresses to pyelonephritis in 20 to 30% of cases [23]. The USPSTF gives a Grade A recommendation for screening all pregnant women for ASB between 12 and 16 weeks of gestation [24]. Nitrofurantoin is generally considered safe in the second and third trimesters but is avoided in the first trimester due to a small signal of birth defects in National Birth Defects Prevention Study data (adjusted OR 1.13, 95% CI 0.83 to 1.54 for any defect), and it is contraindicated at term due to hemolytic anemia risk in the neonate [25].

Dysuria in Older Adults

Older adults present a challenge because bacteriuria is common (up to 50% in women over 80 in long-term care) yet often asymptomatic. The IDSA 2019 clinical practice guideline explicitly recommends against treating asymptomatic bacteriuria in non-pregnant adults, including catheterized patients, because antibiotic treatment does not reduce morbidity and promotes resistance [26]. The presence of pyuria alone, without localizing urinary symptoms, does not constitute an indication for antibiotics in this population.

Dysuria in Men

Dysuria in men warrants broader evaluation because the shorter differential in women (dominated by uncomplicated cystitis) does not apply. Urethritis from sexually transmitted infections, chronic prostatitis, and benign prostatic hyperplasia (BPH) causing turbulent urinary flow must all be considered. The 2021 CDC STI Treatment Guidelines recommend empiric dual therapy with ceftriaxone 500 mg IM and doxycycline 100 mg twice daily for 7 days when gonococcal urethritis is suspected [27].

Preventing Recurrent Dysuria and UTIs

Prevention strategies reduce the frequency of dysuria episodes and limit antibiotic exposure over time.

Behavioral and Non-Pharmacologic Measures

A randomized controlled trial (N=140) published in JAMA Internal Medicine found that increasing daily water intake by 1.5 liters reduced recurrent UTI episodes by 48% over 12 months (mean 1.7 vs. 3.2 episodes, P<0.001) [28]. Postcoital voiding, though widely recommended, has not been validated in prospective trials. Cranberry products have shown inconsistent results: a 2023 Cochrane update of 50 trials (N=8,857) found a modest 27% relative risk reduction in UTI recurrence with cranberry products, primarily in women with recurrent UTIs [29].

Prophylactic Antibiotics

For women meeting the threshold for recurrent UTI (2 or more in 6 months, 3 or more in 12 months), the AUA/CUA/SUFU guideline offers several prophylactic options: continuous low-dose nitrofurantoin 50 to 100 mg nightly, post-coital TMP-SMX 80/400 mg single dose, or self-start therapy where the patient begins a full antibiotic course at symptom onset using a pre-supplied prescription [11]. Prophylactic antibiotic courses typically run 3 to 6 months with reassessment afterward.

As Dr. Kalpana Gupta, infectious disease specialist at Boston University and lead author of the IDSA uncomplicated UTI guideline, has stated: "The goal of prophylaxis is not indefinite antibiotic use but rather breaking the cycle of recurrence while behavioral and anatomic factors are addressed" [11].

The AUA guideline also notes: "Clinicians should counsel patients with recurrent UTI regarding the potential benefits and harms of antimicrobial prophylaxis, including antimicrobial resistance and adverse effects" [11].

Vaginal estrogen in postmenopausal women, methenamine hippurate 1 g twice daily, and D-mannose 2 g daily are non-antibiotic options with supportive (though less definitive) evidence [18].